Activation of PPARγ and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
    • Abstract:
      Environmental exposure to arsenite (As3+) has a strong association with the development of human urothelial cancer (UC) and is the 5th most common cancer in men and the 12th most common cancer in women. Muscle invasive urothelial cancer (MIUC) are grouped into basal or luminal molecular subtypes based on their gene expression profile. The basal subtype is more aggressive and can be associated with squamous differentiation, characterized by high expression of keratins (KRT1, 5, 6, 14, and 16) and epidermal growth factor receptor (EGFR) within the tumors. The luminal subtype is less aggressive and is predominately characterized by elevated gene expression of peroxisome proliferator-activated receptor- gamma (PPARγ) and forkhead box protein A1 (FOXA1). We have previously shown that As3+-transformed urothelial cells (As-T) exhibit a basal subtype of UC expressing genes associated with squamous differentiation. We hypothesized that the molecular subtype of the As-T cells could be altered by inducing the expression of PPARγ and/or inhibiting the proliferation of the cells. Non-transformed and As-T cells were treated with Troglitazone (TG, PPARG agonist, 10 μM), PD153035 (PD, an EGFR inhibitor, 1 μM) or a combination of TG and PD for 3 days. The results obtained demonstrate that treatment of the As-T cells with TG upregulated the expression of PPARγ and FOXA1 whereas treatment with PD decreased the expression of some of the basal keratins. However, a combined treatment of TG and PD resulted in a consistent decrease of several proteins associated with the basal subtype of bladder cancers (KRT1, KRT14, KRT16, P63, and TFAP2A). Our data suggests that activation of PPARγ while inhibiting cell proliferation facilitates the regulation of genes involved in maintaining the luminal subtype of UC. In vivo animal studies are needed to address the efficacy of using PPARγ agonists and/or proliferation inhibitors to reduce tumor grade/stage of MIUC.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      PLoS One. 2016 Jan 19;11(1):e0147362. (PMID: 26783756)
      Thorac Cancer. 2015 Jan;6(1):31-7. (PMID: 26273332)
      Am J Pathol. 2011 Mar;178(3):1350-60. (PMID: 21356385)
      Cell Death Differ. 2017 May;24(5):809-818. (PMID: 28282036)
      Oncotarget. 2014 Aug 15;5(15):6375-86. (PMID: 25071007)
      Nature. 2015 Jan 8;517(7533):209-13. (PMID: 25470039)
      J Cell Physiol. 2002 Jun;191(3):310-9. (PMID: 12012326)
      Gene. 2018 Apr 5;649:14-22. (PMID: 29369787)
      Sci Transl Med. 2014 Jul 9;6(244):244ra91. (PMID: 25009231)
      Am J Pathol. 2001 Aug;159(2):591-7. (PMID: 11485917)
      PLoS One. 2013;8(2):e55997. (PMID: 23409107)
      Cancer Gene Ther. 2014 May;21(5):188-93. (PMID: 24853624)
      Toxicol Appl Pharmacol. 2007 Aug 1;222(3):252-7. (PMID: 17382983)
      Urol Oncol. 2015 Oct;33(10):437-43. (PMID: 26321057)
      J Endocrinol. 1999 Sep;162(3):331-40. (PMID: 10467224)
      Int J Cancer. 2015 Mar 1;136(5):E359-86. (PMID: 25220842)
      BMC Cancer. 2019 Mar 7;19(1):204. (PMID: 30845932)
      Cancer Biol Ther. 2009 Apr;8(7):6-15. (PMID: 19417560)
      Cell Death Differ. 2009 Jan;16(1):103-14. (PMID: 18688264)
      PLoS One. 2018 Dec 14;13(12):e0207877. (PMID: 30550540)
      Histopathology. 1995 Aug;27(2):169-74. (PMID: 8835265)
      J Cell Biol. 1986 Nov;103(5):1945-55. (PMID: 2430980)
      Epidemiology. 1997 Sep;8(5):545-50. (PMID: 9270957)
      Cell. 1999 Oct 29;99(3):239-42. (PMID: 10555139)
      Virchows Arch. 2017 Sep;471(3):337-345. (PMID: 28721490)
      Mol Cancer Res. 2012 Aug;10(8):995-1009. (PMID: 22714124)
      Cancer Cell. 2014 Feb 10;25(2):152-65. (PMID: 24525232)
      BMC Cancer. 2016 Oct 13;16(1):799. (PMID: 27737647)
      CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
      Cell Biol Toxicol. 2011 Dec;27(6):381-96. (PMID: 21927821)
      Toxicol Sci. 2004 May;79(1):56-63. (PMID: 14976345)
      Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2078-83. (PMID: 22308455)
      Sci Rep. 2019 Jan 22;9(1):270. (PMID: 30670749)
      Curr Opin Urol. 2019 Jul;29(4):350-356. (PMID: 31158107)
      Mol Cell. 1998 Feb;1(3):465-70. (PMID: 9660931)
      Cancer Res. 1995 Mar 15;55(6):1296-300. (PMID: 7882325)
      Int J Oncol. 2000 Dec;17(6):1157-64. (PMID: 11078801)
      Epidemiology. 1996 Mar;7(2):117-24. (PMID: 8834549)
      Am J Epidemiol. 1995 Feb 1;141(3):198-209. (PMID: 7840093)
      Nature. 2014 Mar 20;507(7492):315-22. (PMID: 24476821)
      PLoS One. 2016 May 25;11(5):e0156310. (PMID: 27224422)
      PLoS One. 2012;7(5):e36669. (PMID: 22590586)
      Lung Cancer. 2006 Mar;51(3):297-301. (PMID: 16386327)
      J Appl Toxicol. 2010 Jul;30(5):416-30. (PMID: 20186695)
      Environ Health Perspect. 1998 Dec;106(12):825-31. (PMID: 9831543)
      Cancer Invest. 2000;18(2):174-82. (PMID: 10705880)
      Clin Genitourin Cancer. 2017 Dec;15(6):e1063-e1067. (PMID: 28803791)
      Oncogenesis. 2019 Nov 26;8(12):69. (PMID: 31772149)
      Nat Commun. 2016 Jun 20;7:11914. (PMID: 27320313)
      PLoS One. 2012;7(1):e30206. (PMID: 22253920)
      BMC Cancer. 2017 Aug 8;17(1):530. (PMID: 28789622)
      Toxicol Sci. 2004 Aug;80(2):358-66. (PMID: 15129022)
      Sci Rep. 2016 Dec 07;6:38531. (PMID: 27924948)
      Oncogene. 2019 May;38(18):3340-3354. (PMID: 30643195)
      Am J Pathol. 2004 May;164(5):1789-98. (PMID: 15111325)
      Pancreas. 2002 Jan;24(1):1-7. (PMID: 11741176)
      Am J Epidemiol. 1998 Apr 1;147(7):660-9. (PMID: 9554605)
    • Grant Information:
      P20 GM103442 United States GM NIGMS NIH HHS
    • Accession Number:
      0 (Arsenites)
      0 (Biomarkers, Tumor)
      0 (FOXA1 protein, human)
      0 (Hepatocyte Nuclear Factor 3-alpha)
      0 (PPAR gamma)
      0 (Quinazolines)
      0 (Transcription Factors)
      68238-35-7 (Keratins)
      EC 2.7.10.1 (ErbB Receptors)
      I66ZZ0ZN0E (Troglitazone)
      N5509X556J (arsenite)
      TC62B68RSL (4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline)
    • Publication Date:
      Date Created: 20200822 Date Completed: 20201014 Latest Revision: 20210223
    • Publication Date:
      20240105
    • Accession Number:
      PMC7444546
    • Accession Number:
      10.1371/journal.pone.0237976
    • Accession Number:
      32822399